Biotechnology News and Research

RSS

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

26 Oct 2009

Potential link exists between histone mRNA formation and apoptosis

A study from the University of North Carolina at Chapel Hill has identified a key player in a molecular process essential for DNA replication within cells.

26 Oct 2009

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

The Wellcome Trust spends over 600 million pounds each year to support its mission to foster and promote research with the aim to improving human and animal health. This funding supports basic research as well as technology transfer, the transfer of academic knowledge and technology to the corporate environment.

26 Oct 2009

TV program shares insights on epilepsy, diagnosis and treatment

A recent edition of Immunotherapy Weekly reported that the television program 'Sharing Miracles' featured award-winning actor Danny Glover during the month of September. In this episode, the Hollywood star discussed his career and his battle against epilepsy.

24 Oct 2009

FDA issues emergency use authorization for peramivir anti-viral drug

BioCryst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

Curriculum to increase science literacy and generate enthusiasm for life sciences among high school students

A new curriculum called The Great Diseases will bring real-world biomedical research to students in three Boston high schools. The result of a collaboration between scientists from Tufts University School of Medicine and teachers from the Boston Public Schools, the curriculum presents current threats to global health through laboratory learning, multimedia, and case-based studies

24 Oct 2009

Eurogentec to acquire Anaspec, a private proteomics company in California

Eurogentec S.A. (“Eurogentec”) announces today a final agreement for the acquisition of AnaSpec, Inc. (“AnaSpec” or the “Company”), a privately-held proteomics company based in Fremont, California.

24 Oct 2009

Aldevron's new division to produce and sell research and manufacturing services in Wisconsin

Aldevron, a biotechnology company based in Fargo, ND, has today announced that the company is expanding into Madison, WI. The new division will produce and sell contract research and manufacturing services marketed under the Aldevron brand.

24 Oct 2009

UAB to create national database and repository to identify medications for rheumatoid arthritis

The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA).

24 Oct 2009

Pulmo BioTech signs agreement with Biotechnology Consulting Poland for commercialization of PulmoBind

Pulmo BioTech Inc. has announced that it will ultimately receive at least $3.3 million pursuant to the license agreement contemplated by the previously announced non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. with respect to its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development work, clinical trials and ultimately, commercialization in the European market.

24 Oct 2009

Potentia Pharmaceuticals and Alcon Research sign license and purchase option agreements

Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.

24 Oct 2009

MPI Research to assist Kineta in autoimmune drug development program

MPI Research, a preclinical Contract Research Organization (CRO), announced that it will be collaborating with Kineta, Inc, a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system.

24 Oct 2009

Updated data on XL184 study in patients with glioblastoma multiforme presented

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

24 Oct 2009

PPA reaches historic milestone; helps the six millionth person

After visiting more than 3,000 cities in all 50 states, the Partnership for Prescription Assistance (PPA) has reached a historic milestone today by helping the six millionth person at an event in Harrisburg, Pennsylvania.

24 Oct 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

24 Oct 2009

Cohen Independent Research Group publishes a report profiling Nutra Pharma

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that Cohen Independent Research Group has published a report profiling Nutra Pharma Corporation.

24 Oct 2009

avVaa World Health Care Products to launch third Direct TV Media Test

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced their third Direct TV Media Test is scheduled to launch on Thursday October 29.

24 Oct 2009

Bio-Rad Laboratories to acquire diagnostic businesses of Biotest AG for 45 million euros

Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has signed an agreement to acquire certain diagnostic businesses of Biotest AG for 45 million euros.

24 Oct 2009

Biotechnology News and Research

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Potential link exists between histone mRNA formation and apoptosis

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

TV program shares insights on epilepsy, diagnosis and treatment

FDA issues emergency use authorization for peramivir anti-viral drug

Curriculum to increase science literacy and generate enthusiasm for life sciences among high school students

Eurogentec to acquire Anaspec, a private proteomics company in California

Aldevron's new division to produce and sell research and manufacturing services in Wisconsin

UAB to create national database and repository to identify medications for rheumatoid arthritis

Pulmo BioTech signs agreement with Biotechnology Consulting Poland for commercialization of PulmoBind

Potentia Pharmaceuticals and Alcon Research sign license and purchase option agreements

MPI Research to assist Kineta in autoimmune drug development program

Updated data on XL184 study in patients with glioblastoma multiforme presented

PPA reaches historic milestone; helps the six millionth person

Seattle Genetics reports its third-quarter financial results

Cohen Independent Research Group publishes a report profiling Nutra Pharma

avVaa World Health Care Products to launch third Direct TV Media Test

Bio-Rad Laboratories to acquire diagnostic businesses of Biotest AG for 45 million euros

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News